Literature DB >> 8617610

Practice setting and physician influences on judgments of colon cancer treatment by community physicians.

S L McFall1, R B Warnecke, A D Kaluzny, L Ford.   

Abstract

OBJECTIVE: This article compares judgments about the treatment of Dukes' B2 and C colon cancer made by general surgeons to those of internists and family practitioners. Physician and practice variables were specialty, affiliation with a Community Clinical Oncology Program (CCOP) hospital, time in practice, professional centrality (level of participation in cancer information networks), solo practice, and number of colon cancer patients. DATA COLLECTION
METHODS: Data are combined from national probability samples of CCOP- and non-CCOP-affiliated physicians. This study focused on 1,138 internists, family physicians, and general surgeons who participated in decision making for patients diagnosed with Dukes' B2 or C stage colon cancer. Judgments were elicited using brief vignettes. METHODS OF ANALYSIS: Judgments of adjuvant therapy are classified as (a) consistent with the National Institutes of Health Consensus Conference recommendations (experimental for Dukes' B2, accepted for Dukes' C); (b) accepted treatment for both stages; or (c) experimental for both stages. Multinomial logit analyses were used to examine the association of practice setting and physician characteristics to judgments of treatment.
RESULTS: Surgeons and CCOP-affiliated physicians were more likely to endorse the NIH consensus conference position. Surgeons, younger physicians, and those in group practice were more likely to approve of chemotherapy for both cancer stages. The most common position (chemotherapy experimental) was more likely from nonsurgeons, solo practitioners, and non-CCOP physicians.
CONCLUSION: Physician and practice setting characteristics, including organized structures such as the CCOP, are possible mediating structures that can facilitate dissemination of standards of treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8617610      PMCID: PMC1070100     

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  11 in total

1.  Discussion on major surgery in carcinoma of the rectum with or without colostomy, excluding the anal canal and including the rectosigmoid: general results of surgical treatment.

Authors:  C E DUKES
Journal:  Proc R Soc Med       Date:  1957-12

2.  Using a community clinical trials network for treatment, prevention, and control research: assuring access to state-of-the-art cancer care.

Authors:  A D Kaluzny; R Warnecke; L M Lacey; T Johnson; D Gillings; H Ozer
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

3.  The rate of adoption of new procedures among physicians. The impact of specialty and practice characteristics.

Authors:  M P Freiman
Journal:  Med Care       Date:  1985-08       Impact factor: 2.983

Review 4.  Trials of adjuvant chemotherapy in colorectal cancer.

Authors:  J M Gilbert
Journal:  Drugs Exp Clin Res       Date:  1986

Review 5.  Adjuvant therapy of colorectal cancer. Why we still don't know.

Authors:  M Buyse; A Zeleniuch-Jacquotte; T C Chalmers
Journal:  JAMA       Date:  1988-06-24       Impact factor: 56.272

6.  The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy.

Authors:  R Grilli; G Apolone; S Marsoni; A Nicolucci; P Zola; A Liberati
Journal:  Med Care       Date:  1991-01       Impact factor: 2.983

7.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

8.  Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990.

Authors:  K C Chu; R E Tarone; W H Chow; B F Hankey; L A Ries
Journal:  J Natl Cancer Inst       Date:  1994-07-06       Impact factor: 13.506

9.  Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.

Authors:  A D Kaluzny; T Ricketts; R Warnecke; L Ford; J Morrissey; D Gillings; E J Sondik; H Ozer; J Goldman
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

10.  Accrual of patients to randomized clinical trials. Factors affecting cancer prevention and control research.

Authors:  A D Kaluzny; L M Lacey; R Warnecke; J P Morrissey; E J Sondik; L Ford
Journal:  Int J Technol Assess Health Care       Date:  1994       Impact factor: 2.188

View more
  5 in total

1.  The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.

Authors:  Ruili Luo; Sharon H Giordano; Dong D Zhang; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

2.  Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.

Authors:  Christina DeFilippo Mack; M Alan Brookhart; Robert J Glynn; Anne Marie Meyer; William R Carpenter; Robert S Sandler; Til Stürmer
Journal:  Epidemiology       Date:  2015-09       Impact factor: 4.822

3.  Diffusion of surgical innovation among patients with kidney cancer.

Authors:  David C Miller; Christopher S Saigal; Mousumi Banerjee; Jan Hanley; Mark S Litwin
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

4.  Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.

Authors:  Ann Scheck McAlearney; Paula H Song; Kristin L Reiter
Journal:  Contemp Clin Trials       Date:  2012-08-19       Impact factor: 2.226

5.  On the Black-White Disparity in Prostate Cancer Mortality.

Authors:  Otis W Brawley; Sean A Fletcher
Journal:  JNCI Cancer Spectr       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.